April 2022 in “International journal of respiratory and pulmonary medicine” People with lower levels of free testosterone tend to have worse COVID-19 outcomes.
September 2015 in “International Society of Hair Restoration Surgery” June 1985 in “Journal of the American Academy of Dermatology”
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
5 citations
,
October 2021 in “Clinical, cosmetic and investigational dermatology” Japanese patients with alopecia areata often have a higher BMI and consume more vitamin C, fruit, and retinol, which may affect their condition's development or severity.
Baricitinib effectively regrows hair in severe alopecia areata cases.
10 citations
,
March 2023 in “Journal of Managed Care & Specialty Pharmacy” Alopecia areata and atopic dermatitis have similar healthcare costs, but alopecia areata leads to more outpatient and long-term disability expenses.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
1 citations
,
March 2025 in “Pediatric Dermatology” New tools help doctors better assess and treat alopecia areata in kids by considering more than just hair loss.
April 2023 in “Journal of Investigative Dermatology” Patients and doctors often disagree on alopecia areata severity and treatment satisfaction.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
November 2025 in “Journal of Investigative Dermatology” Alopecia areata requires addressing both emotional and financial challenges for better patient care.
2 citations
,
March 2025 in “Journal of Translational Autoimmunity” Targeting the AhR pathway may help treat alopecia areata.
12 citations
,
July 2016 in “Journal of dermatology” Intramuscular triamcinolone acetonide is an effective treatment for severe alopecia areata, especially in males.
March 2026 in “Dermatology Online Journal” Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
Baricitinib may not always prevent relapse in alopecia areata.
February 2025 in “Canadian Journal of Health Technologies” Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
October 2024 in “BMJ Case Reports” Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.
12 citations
,
August 2020 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
23 citations
,
August 2022 in “JAMA Dermatology” Patients with alopecia areata feel less regret about treatment decisions when they are involved in the decision-making process.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
June 2025 in “British Journal of Dermatology” Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
3 citations
,
January 2024 in “Annals of Dermatology” The criteria help doctors diagnose and treat alopecia areata more effectively.
July 2025 in “Journal of the European Academy of Dermatology and Venereology”